Monoclonal antibody · Acts on influenza A virus hemagglutinin · developed by Vir Biotechnology
VIR-2482 is an investigational agent given by intramuscular injection and studied in influenza A.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05567783 | Phase 2 | Influenza A | Terminated | VIR |
| NCT04033406 | Phase 1 | Influenza A | Completed | VIR |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Influenza A
Updated Nov 1, 2026. Something wrong or missing? Report it on the VIR page.
See VIR's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
VIR catalysts and pipeline →